BlackRock Inc. Makes New Investment in Compass Therapeutics, Inc. $CMPX

Key Points

• BlackRock acquired 11.28 million shares of Compass Therapeutics during the second quarter, worth approximately $24.7 million and representing about 6.26% of the company. Institutional investors collectively own 68.43% of CMPX.
• Analyst sentiment is broadly positive, with a “Moderate Buy” consensus and an average price target of $11.77, although ratings range from “Strong Buy” to “Strong Sell.”
• CMPX opened at $2.43, versus a 52-week range of $1.61 to $6.88. The company reported a quarterly loss of $0.13 per share, missing estimates by $0.02, and analysts expect a full-year loss of $0.47 per share.

BlackRock Inc. acquired a new position in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,281,781 shares of the company's stock, valued at approximately $24,707,000. BlackRock Inc. owned approximately 6.26% of Compass Therapeutics as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. LPL Financial LLC lifted its holdings in shares of Compass Therapeutics by 4.7% in the 4th quarter. LPL Financial LLC now owns 44,470 shares of the company's stock worth $239,000 after buying an additional 2,000 shares during the period. Victory Capital Management Inc. increased its stake in shares of Compass Therapeutics by 20.6% during the third quarter. Victory Capital Management Inc. now owns 12,652 shares of the company's stock valued at $44,000 after buying an additional 2,164 shares during the period. Focus Partners Wealth increased its stake in shares of Compass Therapeutics by 16.2% during the third quarter. Focus Partners Wealth now owns 15,805 shares of the company's stock valued at $56,000 after buying an additional 2,206 shares during the period. Invesco Ltd. raised its holdings in shares of Compass Therapeutics by 5.3% in the fourth quarter. Invesco Ltd. now owns 63,901 shares of the company's stock valued at $343,000 after acquiring an additional 3,245 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Compass Therapeutics by 1.9% in the third quarter. Dimensional Fund Advisors LP now owns 175,556 shares of the company's stock valued at $619,000 after acquiring an additional 3,329 shares in the last quarter. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on CMPX. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Compass Therapeutics in a research note on Friday, July 17th. LADENBURG THALM/SH SH started coverage on shares of Compass Therapeutics in a report on Wednesday, July 1st. They issued a "buy" rating and a $5.00 price target for the company. Piper Sandler upped their price target on shares of Compass Therapeutics from $4.00 to $6.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th. Wall Street Zen downgraded shares of Compass Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 8th. Finally, Citigroup reissued a "market outperform" rating on shares of Compass Therapeutics in a report on Thursday, June 4th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $11.77.

Compass Therapeutics Price Performance

CMPX opened at $2.43 on Thursday. The firm has a market capitalization of $437.61 million, a PE ratio of -6.08 and a beta of 0.95. The business's 50-day moving average is $2.21 and its two-hundred day moving average is $3.35. Compass Therapeutics, Inc. has a 1 year low of $1.61 and a 1 year high of $6.88.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). As a group, sell-side analysts expect that Compass Therapeutics, Inc. will post -0.47 EPS for the current year.

Compass Therapeutics Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source